New data shows evolocumab improves features of plaque stability post-ACS

Sponsored by Amgen Australia Pty Ltd

The addition of PCSK9 inhibitor evolocumab to optimised statin therapy improves features of plaque stability after acute coronary syndrome (ACS), according to a study presented by Australian cardiologist Professor Stephen Nicholls in a late-breaking session at the European Society of Cardiology (ESC) Congress 2021.1 This new data adds to the growing evidence of the impact ...

Already a member?

Login to keep reading.

© 2021 the limbic